About GeneMedi
G eneMedi is a leading global biotechnology enterprise focusing on gene therapy vector development and therapeutic target validation. By delivering powerful gene and cell therapy (GCT) vectors, adeno-associated virus (AAV) optimization packages, and chimeric viral vectors (CVV), GeneMedi supports preclinical pharmaceutical companies, translation centers, and advanced laboratories worldwide. Specializing in cell-specific gene regulation and high-expression viral engineering, GeneMedi provides ready-to-use research tools alongside customized molecular systems. These products resolve high-complexity vector challenges in CRISPR gene editing, RNA silencing, oncolytic research, and antigen/vaccine discovery.
Core Solutions & Capability Portfolio
We work in collaboration with GeneMedi to provide researchers with state-of-the-art gene delivery platforms and therapeutics validation systems:
GCT Solutions (Gene & Cell Therapy)
Advanced toolsets for preclinical gene modification and cell therapeutic discovery. Provides high-delivery transfection reagents and custom cloning services.
- Lentivirus expression vectors for stable cell line generation
- CRISPR/Cas9 knockout & activation plasmid cloning
- Highly efficient transfection reagents for cell lines
AAV Solutions (Adeno-Associated Virus)
Optimized AAV vector generation with tissue-specific promoters and specific serotype capsids (AAV1-AAV9, AAV-PHP.B, etc.) for in vivo targeting.
- Ready-to-inject pre-made AAV control vectors (GFP/mCherry)
- Custom AAV packaging for RNAi and gene overexpression
- Tissue-specific promoter selection validation
CVV Solutions (Chimeric Viral Vector)
Advanced viral vectors optimized for diagnostic verification and vaccine development, offering structured antigen display and high immunogenicity.
- Chimeric viral vectors displaying specific viral spike proteins
- Oncolytic adenoviral vector customization
- Antigen-presenting pseudovirus particles
Proteins & Benchmark Antibodies
Recombinant therapeutic target proteins and monoclonal antibodies validated against benchmark biosimilars for target evaluation assays.
- Benchmark therapeutic antibodies (biosimilars)
- Bioactive cytokine receptors and transmembrane targets
- COVID-19 / Influenza recombinant antigen proteins
Scientific Impact & Capabilities
GeneMedi's robust research vectors are designed to meet clinical and preclinical guidelines, providing:
“Striving to accelerate gene therapy translation by supplying highly optimized AAV, lentiviral, and chimeric vectors to validate targets and deliver therapeutic genes.”
GeneMedi
- Partner : GeneMedi
- Category : Gene & Cell Therapy (GCT)
- Region : AAV, Lentivirus, CVV
- Collaboration : Stellvard Bioscience
- Key Offerings : Vector Engineering & Targets